InvestorsHub on MSN
Aligos Therapeutics edges higher after update on Phase 2 HBV trial
Shares of Aligos Therapeutics Inc (NASDAQ:ALGS) rose 3.1% on Wednesday after the company provided a progress update on its ...
Pharmaceutical Technology on MSN
GSK to file for approval of twice-yearly hep B drug on positive Phase III data
GSK will be filing for approval of bepirovirsen in hepatitis B to global regulatory authorities based on the Phase III data.
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that it will be presenting new data from its Phase 2 trials evaluating the potential clinical impact that VIR-3434 ...
Hepatitis B viral load is the amount of hepatitis B virus (HBV) found in a person’s bloodstream. Hepatitis B is a viral infection that can pass from person to person through bodily fluids. It ...
Three scenarios can occur after spontaneous seroconversion from HBeAg to anti-HBe: Most individuals go into the inactive hepatitis B phase ("inactive carrier"), characterized by normalization of serum ...
A second protocol defined interim analysis is planned when approximately 50% (or 55) HBeAg+ participants complete 24 weeks of the treatment period. This enrollment milestone occurred in January 2026.
Arbutus Biopharma Corporation announced plans to initiate a Phase 2b clinical trial in the first half of 2025 after reporting promising results from its Phase 2a trial, where a significant functional ...
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced it will be presenting new data from its ongoing Phase 2 SOLSTICE and MARCH trials evaluating the potential ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results